1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

Sunshine Biopharma Introduces Ursodiol for Cholestatic Liver Diseases

26 Nov 2024
Admin
News Article

Sunshine Biopharma Introduces Ursodiol for Cholestatic Liver Diseases

Sunshine Biopharma introduces new drug, Ursodiol for management of cholestatic liver diseases, including PBC

Overview

Sunshine Biopharma Inc., a pharmaceutical company offering and researching lifesaving medicines in a variety of therapeutic areas including oncology and antivirals, announced that its wholly owned Canadian subsidiary, Nora Pharma Inc., has launched a new generic prescription drug.

About the Drug: Ursodiol

The newly launched drug is Ursodiol, a generic version of URSO DS.
Ursodiol, also known as ursodeoxycholic acid (UDCA), is indicated for the management of cholestatic liver diseases, including primary biliary cirrhosis (PBC).
Ursodiol is also used to
(i) dissolve gallstones in people who do not want surgery or cannot have surgery to remove gallstones, or
(ii) prevent the formation of gallstones in overweight people engaged in a rapid weight loss program.
Nora Pharma’s Ursodiol is available for the Canadian market in 250 mg and 500 mg tablets.

Market size of Ursodiol: In Canada

The market size of Ursodiol in Canada is part of the broader global Ursodiol market, which is projected to grow significantly.
The global Ursodiol market was valued at approximately $457.9 million in 2022 and is expected to reach around $933.9 million by 2029, with a compound annual growth rate (CAGR) of 10.7%.

Words from the CEO: Sunshine Biopharma

“This is the third new product we have introduced this year. We continue to grow through the addition of new products to strengthen our presence in the Canadian generic drugs market which was estimated to be $9.7 billion in 2023 and is projected to grow to $19.2 billion by 2032,” said Dr. Steve Slilaty, CEO of Sunshine Biopharma.

Sunshine Biopharma: Current Generic Drugs

Sunshine Biopharma currently has 63 generic prescription drugs on the market in Canada and 31 additional drugs scheduled to be launched in the remainder of 2024 and in 2025.